tiprankstipranks
Trending News
More News >
Vir Biotechnology (VIR)
NASDAQ:VIR
US Market

Vir Biotechnology (VIR) Stock Forecast & Price Target

Compare
1,351 Followers
See the Price Targets and Ratings of:

VIR Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Vir
Biotechnology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$17.88
▲( 297.33% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $17.88 with a high forecast of $31.00 and a low forecast of $12.00. The average price target represents a 297.33% change from the last price of $4.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","11.75":"$11.75","18.5":"$18.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.75,18.5,25.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.08,7.996923076923077,9.913846153846155,11.830769230769231,13.747692307692308,15.664615384615384,17.581538461538464,19.49846153846154,21.415384615384617,23.332307692307694,25.24923076923077,27.166153846153847,29.083076923076923,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.08,6.987692307692308,7.895384615384615,8.803076923076922,9.71076923076923,10.618461538461538,11.526153846153846,12.433846153846153,13.34153846153846,14.249230769230769,15.156923076923077,16.064615384615383,16.97230769230769,{"y":17.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.08,6.535384615384616,6.990769230769231,7.446153846153846,7.901538461538461,8.356923076923078,8.812307692307693,9.267692307692307,9.723076923076924,10.178461538461539,10.633846153846154,11.08923076923077,11.544615384615385,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.12,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$31.00Average Price Target$17.88Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$14
Buy
211.11%
Upside
Reiterated
05/22/25
H.C. Wainwright Analyst forecast on VIR
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$110$15
Buy
233.33%
Upside
Reiterated
05/20/25
Bank of America Securities Analyst forecast on VIR
Alec StranahanBank of America Securities
Bank of America Securities
$13$12
Hold
166.67%
Upside
Reiterated
05/15/25
Leerink Partners Analyst forecast on VIR
Roanna RuizLeerink Partners
Leerink Partners
$20$16
Buy
255.56%
Upside
Reiterated
05/10/25
Barclays Analyst forecast on VIR
Gena WangBarclays
Barclays
$31
Buy
588.89%
Upside
Reiterated
05/08/25
TD Cowen Analyst forecast on VIR
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
05/08/25
Morgan Stanley Analyst forecast on VIR
Michael UlzMorgan Stanley
Morgan Stanley
$20
Buy
344.44%
Upside
Reiterated
05/08/25
J.P. Morgan Analyst forecast on VIR
Eric JosephJ.P. Morgan
J.P. Morgan
$14
Hold
211.11%
Upside
Reiterated
05/07/25
Goldman Sachs Analyst forecast on VIR
Paul ChoiGoldman Sachs
Goldman Sachs
$28$21
Buy
366.67%
Upside
Reiterated
04/16/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$14
Buy
211.11%
Upside
Reiterated
05/22/25
H.C. Wainwright Analyst forecast on VIR
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$110$15
Buy
233.33%
Upside
Reiterated
05/20/25
Bank of America Securities Analyst forecast on VIR
Alec StranahanBank of America Securities
Bank of America Securities
$13$12
Hold
166.67%
Upside
Reiterated
05/15/25
Leerink Partners Analyst forecast on VIR
Roanna RuizLeerink Partners
Leerink Partners
$20$16
Buy
255.56%
Upside
Reiterated
05/10/25
Barclays Analyst forecast on VIR
Gena WangBarclays
Barclays
$31
Buy
588.89%
Upside
Reiterated
05/08/25
TD Cowen Analyst forecast on VIR
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
05/08/25
Morgan Stanley Analyst forecast on VIR
Michael UlzMorgan Stanley
Morgan Stanley
$20
Buy
344.44%
Upside
Reiterated
05/08/25
J.P. Morgan Analyst forecast on VIR
Eric JosephJ.P. Morgan
J.P. Morgan
$14
Hold
211.11%
Upside
Reiterated
05/07/25
Goldman Sachs Analyst forecast on VIR
Paul ChoiGoldman Sachs
Goldman Sachs
$28$21
Buy
366.67%
Upside
Reiterated
04/16/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

1 Month
xxx
Success Rate
9/22 ratings generated profit
41%
Average Return
-5.63%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.91% of your transactions generating a profit, with an average return of -5.63% per trade.
3 Months
xxx
Success Rate
8/22 ratings generated profit
36%
Average Return
-10.24%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -10.24% per trade.
1 Year
Gena WangBarclays
Success Rate
5/22 ratings generated profit
23%
Average Return
-20.13%
reiterated a buy rating 17 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 22.73% of your transactions generating a profit, with an average return of -20.13% per trade.
2 Years
xxx
Success Rate
2/22 ratings generated profit
9%
Average Return
-39.73%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -39.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
15
13
14
8
9
Buy
4
3
3
1
2
Hold
11
5
4
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
21
21
10
14
In the current month, VIR has received 11 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 17.88.
Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is -$0.74 with a range of -$1.00 to -$0.54. The previous quarter’s EPS was -$0.88. VIR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year VIR has Outperformed its overall industry.
Next quarter’s earnings estimate for VIR is -$0.74 with a range of -$1.00 to -$0.54. The previous quarter’s EPS was -$0.88. VIR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year VIR has Outperformed its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $2.38M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $3.03M. VIR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.37% of the time in the same period. In the last calendar year VIR has Outperformed its overall industry.
Next quarter’s sales forecast for VIR is $2.38M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $3.03M. VIR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.37% of the time in the same period. In the last calendar year VIR has Outperformed its overall industry.

VIR Stock Forecast FAQ

What is VIR’s average 12-month price target, according to analysts?
Based on analyst ratings, Vir Biotechnology’s 12-month average price target is 17.88.
    What is VIR’s upside potential, based on the analysts’ average price target?
    Vir Biotechnology has 297.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VIR a Buy, Sell or Hold?
          Vir Biotechnology has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Vir Biotechnology’s price target?
            The average price target for Vir Biotechnology is 17.88. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $31.00 ,the lowest forecast is $12.00. The average price target represents 297.33% Increase from the current price of $4.5.
              What do analysts say about Vir Biotechnology?
              Vir Biotechnology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of VIR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis